Whitefort Capital Amends Arbutus Biopharma Stake

Ticker: ABUS · Form: SC 13D/A · Filed: 2024-05-17T00:00:00.000Z

Sentiment: neutral

Topics: 13D-filing, amendment, shareholder-activity

TL;DR

Whitefort Capital updated their Arbutus Biopharma filing on 5/17. Watch for changes.

AI Summary

Whitefort Capital Management, LP has amended its Schedule 13D filing regarding Arbutus Biopharma Corporation, as of May 17, 2024. The filing indicates a change in beneficial ownership, though specific share counts or dollar amounts are not detailed in this excerpt. This amendment updates information previously filed by Whitefort Capital Management, LP concerning their holdings in Arbutus Biopharma.

Why It Matters

This filing signals a potential shift in major shareholder interest or strategy for Arbutus Biopharma, which could influence its stock price and future corporate actions.

Risk Assessment

Risk Level: medium — Amendments to 13D filings can indicate activist investor activity or significant changes in a major shareholder's position, warranting close monitoring.

Key Players & Entities

FAQ

What specific changes in beneficial ownership are detailed in this Amendment No. 1 to the Schedule 13D?

This excerpt does not specify the exact changes in beneficial ownership, only that an amendment has been filed by Whitefort Capital Management, LP.

When was the previous Schedule 13D filing made by Whitefort Capital Management, LP?

The filing date for this Amendment No. 1 is May 17, 2024, but the date of the original filing is not provided in this excerpt.

What is the CUSIP number for Arbutus Biopharma Corporation's common shares?

The CUSIP number for Arbutus Biopharma Corporation's common shares is 03879J100.

What is the business address of Arbutus Biopharma Corporation?

The business address of Arbutus Biopharma Corporation is 701 Veterans Circle, Warminster, PA 18974.

What was Arbutus Biopharma Corporation's former company name?

Arbutus Biopharma Corporation was formerly known as Tekmira Pharmaceuticals Corp, with name changes noted on June 7, 2011, and October 3, 2008.

From the Filing

0001193805-24-000672.txt : 20240517 0001193805-24-000672.hdr.sgml : 20240517 20240517090323 ACCESSION NUMBER: 0001193805-24-000672 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20240517 DATE AS OF CHANGE: 20240517 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Arbutus Biopharma Corp CENTRAL INDEX KEY: 0001447028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 980597776 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-85963 FILM NUMBER: 24957870 BUSINESS ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 BUSINESS PHONE: 604-419-3200 MAIL ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS Corp DATE OF NAME CHANGE: 20110607 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20081003 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Whitefort Capital Management, LP CENTRAL INDEX KEY: 0001884931 ORGANIZATION NAME: IRS NUMBER: 820808818 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 12 E. 49TH STREET STREET 2: 40TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 2122594370 MAIL ADDRESS: STREET 1: 12 E. 49TH STREET STREET 2: 40TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 SC 13D/A 1 sc13da114125002_05172024.htm AMENDMENT NO. 1 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1) 1 Arbutus Biopharma Corporation (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 03879J100 (CUSIP Number) DAVID SALANIC Joseph Kaplan WHITEFORT CAPITAL MANAGEMENT, LP 12 East 49th Street, 40th Floor New York, New York 10017 ELIZABETH GONZALEZ-SUSSMAN OLSHAN FROME WOLOSKY LLP 1325 Avenue of the Americas New York, New York 10019 (212) 451-2300 Patricia Olasker Davies Ward Phillips & Vineberg LLP 155 Wellington Street West Toronto, ON M5V 3J7 (416) 863-0900 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) May 17, 2024 (Date of Event Which Requires Filing of This Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☒. Note:   Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.   See § 240.13d-7 for other parties to whom copies are to be sent. 1               The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes ). CUSIP No. 03879J100 1 NAME OF REPORTING PERSON Whitefort Capital Master Fund, LP 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐ 3 SEC USE ONLY 4 SOURCE OF FUNDS WC 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ☐ 6 CITIZENSHIP

View on Read The Filing